Waldenström macroglobulinemia (WM) is a rare form of lymphoma characterized by an infiltration of lymphoplasmacytic cells in bone marrow and immunoglobulin M monoclonal gammopathy.
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The phenotypic frequency of the CD3 -
CD56
dim cytotoxic NK-cell subset was further investigated on a Gallios (Beckman-Coulter) flow cytometer, while gating out CD3 -
bright cell. The frequency of CD56 dim NK cells from WM patients was indistinguishable from those of controls in terms of the cell-surface expression of NK receptors (FcγRIIIA/CD16, NKG2A, NKG2D, NKG2C, ILT-2, LAIR1, DNAM-1, NKp80, and 2B4) ( Figure 1E and data not shown) . However, it is important to note that mean of fluorescence intensity (MFI) values for CD16 are significantly increased in WM patients, regardless of the presence or not of circulating B-cell clone, as compared to controls ( Figures 1E). In addition, the early activation marker CD69 is increased in WM both in absolute value and percentage ( Figure 1F) , whereas it is decreased in chronic lymphocytic leukemia (CLL).
5 Notably, the expression of each tested receptor seemed remarkably stable over a 1-year period (Online Supplementary Appendix). More importantly, CD57, a marker associated with terminal NK differentiation, 9 was profoundly increased in the WM patients, both in percentage and absolute value, and particularly in those with a circulating B-cell clone ( Figure 1G ). These data are consistent with those reported by Li et al. 10 showing that CD57 + cytotoxic T cells are increased in patients with WM. CD57 was also frequently reported in the association with several cancers, and was strongly linked to a less severe disease and a better outcome, in sharp contrast to what was observed for CD8 + T cells. 11 We also observed a weaker expression of the activating NK receptors NKp30 in WM patients compared with controls ( Figures 1H). In addition, Figure 1H shows an inverse correlation between CD57 and NKp30 expressions, which is highly more significant in WM patients (Spearman test: r=-0.91, P<0.0001), than in healthy controls haematologica 2015; 100:e149 (Spearman test: r=-0.49, P=0.01), and that had been previously reported as being related to differentiation of NK cells. Taken together, these data suggest that CD56 dim NK cells in WM are more differentiated in patients with a circulating B-cell clone. Similar modulations of the NK-cell repertoire have been described in elderly individuals 4 and in patients with acute leukemia, 12 but not with CLL.
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We further assessed the overall cytolytic activity of NK cells from WM patients. Direct cytotoxicity was performed against K562 target cells. NK cells were purified from fresh peripheral blood mononuclear cells (PBMCs) at the Flow Cytometry Core CyPS (Pitié-Salpêtrière hospital) with a cell-sorting BD FACSAria II flow cytometer. The purification of CD3 -CD56
+ NK cells was more than 98%. Direct cytotoxicity was assessed on purified NK cells before or after IL-2 stimulation (1,000 U/ml, Proleukin, Chiron) for 48 h with a standard 51 Cr-release assay against the K562 cell line, at a different effector/target (E:T) cell ratio. 5, 6 A slight but non-significant decrease in the cytotoxicity mediated by non-or IL2-activated NK cells was observed in the group of WM patients with a circulating B-cell clone compared with two other groups (Figure 2A ). Of note, granzyme-B and perforin were expressed at equivalent levels in all samples (Online Supplementary Appendix).
Antibody-dependent cellular cytotoxicity (ADCC) assays were performed with purified non-activated NK cells in the presence of 51 Cr-labeled Raji target cells or purified autologous peripheral blood B cells, at an effector ratio of 1:10 in the presence of anti-CD20 rituximab (Roche Ltd.) or ublituximab (LFB Biotech), an optimized anti-CD20 mAb characterized by a low fucose content in its Fc region that improves FcγRIIIA (CD16) binding and consequently increases ADCC activity.
13 ADCC against Raji cells was significantly increased in the presence of 1 ng/mL of ublituximab, compared with rituximab, in all groups ( Figure 2B , left panel). However, ADCC against autologous B cells was significantly increased in WM patients with a circulating Bcell clone only in the presence of ublituximab, and not of rituximab ( Figure 2B, right panel) . The comparison of ADCC mediated in the presence of Raji cells and autologous B cells revealed that ADCC efficacy is more dependent on the intrinsic resistance to the tumor target cells than on the NK functionality. Additional support for the findings of the ADCC assays was provided from the degranulation capacities of NK cells, which are highlighted by CD107a cell-surface expression by flow cytometry in the presence of these two anti-CD20 mAbs, as described. 6 Indeed, regardless of the concentration, ublituximab triggered better effector functions to clear WM cells in patients with a circulating B-cell clone compared with rituximab ( Figure  2C ), which is consistent with findings in CLL patients.
5,6
Importantly, the percentage of CD107a + NK cells significantly correlated with the frequency of circulating B-cell clones only in the presence of ublituximab ( Figure 2D ).
Taken together, these data show that the efficacy of NK cells against B-cell clones is greater with ublituximab than with rituximab, allowing the NK phenotypic features observed in WM to be bypassed.
Finally, our findings provide additional insights into the cellular mechanisms underlying the clinical activity of optimized anti-CD20 mAbs. An ongoing phase I/II study of ublituximab (NCT01647971) to evaluate monotherapy in rituximab-relapse and refractory B-cell lymphoid malignancies, including WM, shows promising early results.
